Frits van Rhee, MD, PhD
Frits van Rhee is a Professor of Medicine and Clinical Director of the UAMS Myeloma Center. He earned his medical degree from Erasmus University, Rotterdam, Netherlands and his PhD at the Imperial College of Science, Medicine and Technology, University of London. Dr. Frits van Rhee trained in Internal Medicine and Hematology in the UK, and in Bone Marrow Transplantation at John Radcliffe University Hospital in Oxford and the Royal Postgraduate Medical School in London. He holds the Charles and Clydene Scharlau Chair for Hematological Malignancies.
Dr. van Rhee is an international expert on Castleman Disease, with one of the largest populations of Castleman Disease patients in the world. He also is an expert in multiple myeloma and other hematologic malignancies, with a research focus in immunotherapy.
Dr. van Rhee is a member of the International Society for Cellular Therapy, the International Society for Experimental Hematology, the European Group for Bone and Marrow Transplantation, the Royal college of Physicians (UK), the Royal College of Pathologists (UK), and the American Society of Hematology. He has UK board certification in Internal Medicine and Hematology.
Representative Publications:
Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes
Mafb Protein Confers Intrinsic Resistance to Proteasome Inhibitors in Multiple Myeloma
The Presence of Large Focal Lesions is a Strong Independent Prognostic Factor in Multiple Myeloma
Kinase Domain Activation Through Gene Rearrangement in Multiple Myeloma
Treatment to Suppression of Focal Lesions on Positron Emission Tomography-Computed Tomography is a Therapeutic Goal in Newly Diagnosed Multiple Myeloma
